OBJECTIVE TEST FOR EARLY PARKINSONS SYNDROME
早期帕金森综合症的客观测试
基本信息
- 批准号:2766808
- 负责人:
- 金额:$ 37.62万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1996
- 资助国家:美国
- 起止时间:1996-06-05 至 2000-04-30
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
DESCRIPTION: (Applicant's Abstract) The goal of the proposed project is to
develop a battery of tests (PD Battery) that could provide an inexpensive
and objective aid for, first, the early diagnosis of Parkinson's syndrome
(PS) and second, to aid in its differential diagnosis, such as idiopathic
Parkinson's disease (iPD); Parkinson-Plus syndromes (P-Plus) such as
striato-nigral degeneration; and essential tremor (ET) as distinguished from
tremor predominant parkinsonism and others. The PD Battery has been
developed that, in preliminary studies, clearly distinguishes between normal
control (NC) subjects and patients with early mild presumptive iPD (95
percent sensitivity, 94 percent specificity and the area under the
receiver-operator curve [ROC] of 0.98). The battery incorporates tests of
motor function, olfaction, and affective state (i.e., depression). When
additional NC subjects and iPD patients were studied in a prospective
manner, the test battery correctly identified 44 of 48 NC subjects and 10 of
the 11 iPD patients. In addition, 7 of 9 patients with ET had test results
in the normal range suggesting that the battery can aid in the
differentiation of tremor predominant iPD and ET.
The next step is to validate the PD Battery by prospectively testing
patients in whom PS is suspected but the diagnosis is uncertain (the
Uncertain PS group). These patients will undergo the PD Battery, Unified
Parkinson Disease Rating Scale (UPDRS) upon entrance into the study. Two
years later, a MRI scan and the UPDRS and motor testing before and after
levodopa administration will be done. These tests should identify which of
these patients become probably normal, probably iPD or Probable P-Plus.
Results of these evaluations will be correlated with their results from the
PD Battery at time of entrance into the study. To further validate the
battery, more NC subjects and patients with: 1) newly diagnosed and mildly
affected PS; 2) P-Plus syndromes; 3) ET; 4) mild Alzheimer's disease (AD)
and 5) AD with parkinsonian features (AD/PD) will be tested.
If successful, the PD Battery could help assure appropriate patients receive
appropriate care, thus, minimizing health costs and disability. In the
future, the PD Battery could allow early or pre-clinical detection of
persons at risk. this battery for early detection, coupled with future
neuro-protective therapies, could further reduce health costs and
disability. In addition , the test battery could be used in the future to
aid research into the possible genetic and/or environmental causes of iPD.
描述:(申请人摘要)拟议项目的目标是
开发一组测试(PD电池),可以提供一个廉价的
和客观的帮助,首先,帕金森综合征的早期诊断
(PS)第二,有助于鉴别诊断,如特发性
帕金森氏病(iPD);帕金森综合征(P-Plus),如
黑质纹状体变性;和特发性震颤(ET),
震颤为主的帕金森病和其他。 PD电池已经
在初步研究中,它清楚地区分了正常的
对照(NC)受试者和早期轻度推定iPD患者(95
94%的灵敏度,94%的特异性和
受试者-操作者曲线[ROC]为0.98)。 该电池包含以下测试
运动功能、嗅觉和情感状态(即,抑郁症)。 当
在一项前瞻性研究中,对额外的NC受试者和iPD患者进行了研究。
以这种方式,测试组合正确地识别了48名NC受试者中的44名和10名NC受试者中的10名。
11例iPD患者 此外,9例ET患者中有7例有检测结果
在正常范围内,这表明电池可以帮助
鉴别震颤为主的iPD和ET。
下一步是通过前瞻性测试验证PD电池
疑似PS但诊断不确定的患者(
不确定PS组)。 这些患者将接受PD组合,统一
帕金森病评定量表(PDRS)。 两
几年后,MRI扫描和运动测试前后,
将进行左旋多巴给药。 这些测试应该确定哪些
这些患者可能变得正常,可能是iPD或可能是P-Plus。
这些评价的结果将与其在
进入研究时的PD电池。 为了进一步验证
组合,更多的NC受试者和患者:1)新诊断和轻度
受累PS; 2)P-Plus综合征; 3)ET; 4)轻度阿尔茨海默病(AD)
和5)将测试具有帕金森特征的AD(AD/PD)。
如果成功,PD电池可以帮助确保适当的患者接受
适当的护理,从而最大限度地减少医疗费用和残疾。 在
未来,PD电池可以允许早期或临床前检测
处于危险中的人。 这种电池用于早期检测,
神经保护疗法,可以进一步降低健康成本,
残疾。 此外,该试验电池将来可用于
帮助研究iPD的可能遗传和/或环境原因。
项目成果
期刊论文数量(4)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Early detection of probable idiopathic Parkinson's disease: I. Development of a diagnostic test battery
- DOI:10.1002/1531-8257(200005)15:3<467::aid-mds1007>3.0.co;2
- 发表时间:2000-05-01
- 期刊:
- 影响因子:8.6
- 作者:Montgomery, EB;Koller, WC;Lyons, K
- 通讯作者:Lyons, K
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Erwin B. Montgomery其他文献
Postpolio syndrome--response to deprenyl (selegiline).
脊髓灰质炎后综合征——对地普尼(司来吉兰)的反应。
- DOI:
10.3109/00207459309000603 - 发表时间:
1993 - 期刊:
- 影响因子:0
- 作者:
Colin R. Bamford;Erwin B. Montgomery;Jorge E Munoz;Carol Stumpf;Sherry Pry;Norman S. Namerow - 通讯作者:
Norman S. Namerow
Case 6
案例6
- DOI:
10.1016/b978-0-12-822829-6.00006-0 - 发表时间:
2021 - 期刊:
- 影响因子:0
- 作者:
Erwin B. Montgomery - 通讯作者:
Erwin B. Montgomery
A Patient Revoking Consent During Awake Craniotomy: An Ethical Challenge
患者在清醒开颅手术期间撤销同意:伦理挑战
- DOI:
- 发表时间:
2007 - 期刊:
- 影响因子:0
- 作者:
P. Ford;N. Boulis;Erwin B. Montgomery;A. Rezai - 通讯作者:
A. Rezai
Evaluation of surgery for Parkinson's disease: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.
- DOI:
10.1212/wnl.55.1.154 - 发表时间:
2000-07 - 期刊:
- 影响因子:9.9
- 作者:
Erwin B. Montgomery - 通讯作者:
Erwin B. Montgomery
Erwin B. Montgomery的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Erwin B. Montgomery', 18)}}的其他基金
PHYSIOLOGY AND PATHOPHYSIOLOGY OF BASAL GANGLIA IN PARKINSON?S DISEASE
帕金森病基底节的生理学和病理生理学
- 批准号:
8173075 - 财政年份:2010
- 资助金额:
$ 37.62万 - 项目类别:
PHYSIOLOGY AND PATHOPHYSIOLOGY OF BASAL GANGLIA IN PARKINSON?S DISEASE
帕金森病基底节的生理学和病理生理学
- 批准号:
7958746 - 财政年份:2009
- 资助金额:
$ 37.62万 - 项目类别:
PHYSIOLOGY AND PATHOPHYSIOLOGY OF BASAL GANGLIA IN PARKINSON?S DISEASE
帕金森病基底节的生理学和病理生理学
- 批准号:
7716418 - 财政年份:2008
- 资助金额:
$ 37.62万 - 项目类别:
PHYSIOLOGY AND PATHOPHYSIOLOGY OF BASAL GANGLIA IN PARKINSON?S DISEASE
帕金森病基底节的生理学和病理生理学
- 批准号:
7349428 - 财政年份:2006
- 资助金额:
$ 37.62万 - 项目类别:
PHYSIOLOGY AND PATHOPHYSIOLOGY OF BASAL GANGLIA
基底节的生理学和病理生理学
- 批准号:
7165695 - 财政年份:2005
- 资助金额:
$ 37.62万 - 项目类别:
相似海外基金
Development and Translation Mass Spectrometry Methods to Determine BioMarkers for Parkinson's Disease and Comorbidities
确定帕金森病和合并症生物标志物的质谱方法的开发和转化
- 批准号:
2907463 - 财政年份:2024
- 资助金额:
$ 37.62万 - 项目类别:
Studentship
Development of a predictive biomarker for Parkinson's disease
帕金森病预测生物标志物的开发
- 批准号:
MR/Y019415/1 - 财政年份:2024
- 资助金额:
$ 37.62万 - 项目类别:
Research Grant
Promoting Parkinson's disease trial participation in rural and coastal communities
促进农村和沿海社区参与帕金森病试验
- 批准号:
2898794 - 财政年份:2024
- 资助金额:
$ 37.62万 - 项目类别:
Studentship
The Diagnostic and Prognostic Utility of Eye Tracking in Parkinson's Disease and Related Disorders
眼动追踪在帕金森病及相关疾病中的诊断和预后效用
- 批准号:
479285 - 财政年份:2023
- 资助金额:
$ 37.62万 - 项目类别:
Operating Grants
Neurophysiological mechanism underlying freezing of gait in Parkinson's disease: transcutaneous spinal cord stimulation for gait disturbance
帕金森病步态冻结的神经生理机制:经皮脊髓刺激治疗步态障碍
- 批准号:
23K10409 - 财政年份:2023
- 资助金额:
$ 37.62万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Inhibition of cell-to-cell propagation of alpha-synuclein aggregation by glial cells and its involvement in neuropathology in Parkinson's disease.
神经胶质细胞抑制α-突触核蛋白聚集的细胞间传播及其参与帕金森病的神经病理学。
- 批准号:
23K06928 - 财政年份:2023
- 资助金额:
$ 37.62万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Propagation of a-synuclein in Parkinson's disease progress
α-突触核蛋白在帕金森病进展中的传播
- 批准号:
22KJ2095 - 财政年份:2023
- 资助金额:
$ 37.62万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Drug-microbiome-host interactions in Parkinson's disease
帕金森病的药物-微生物组-宿主相互作用
- 批准号:
2881438 - 财政年份:2023
- 资助金额:
$ 37.62万 - 项目类别:
Studentship
Ordering the disordered in Parkinson's disease to derive peptide inhibitors of alpha-synuclein toxicity
命令帕金森病患者衍生出α-突触核蛋白毒性的肽抑制剂
- 批准号:
2884235 - 财政年份:2023
- 资助金额:
$ 37.62万 - 项目类别:
Studentship
MICA: How does the pedunculopone nucleus influence treatment responses in Parkinson's disease, and can it be targeted for new treatment strategies
MICA:脚核如何影响帕金森病的治疗反应,是否可以作为新治疗策略的目标
- 批准号:
MR/X005267/1 - 财政年份:2023
- 资助金额:
$ 37.62万 - 项目类别:
Research Grant